MLL/KMT2A antibody (AA 3751-3968)

Catalog No. ABIN969286

Product Details anti-MLL/KMT2A Antibody

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Binding Specificity: AA 3751-3968

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MLL/KMT2A antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Purpose: MLL Antibody

Purification: Ascitic fluid

Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. Coli.

Clone: 10F8D7

Isotype: IgG1

Application Details

Application Notes: ELISA: 1/10000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

References for anti-MLL/KMT2A antibody (ABIN969286)

Nigro, Sainati, Leszl, Mirabile, Spinelli, Consarino, Di Cataldo, Magro, Felix, Basso: "Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 2, pp. 360-2, (2007) (PubMed).

Partida-Pérez, Domínguez, Sánchez-Corona, Castañeda-Cisneros, García-González, López-Cardona, Rivera: "Constitutional duplication 11q23 de novo involving the MLL gene." in: Genetic counseling (Geneva, Switzerland), Vol. 17, Issue 2, pp. 155-9, (2006) (PubMed).

Kadkol, Bruno, Oh, Schmidt, Lindgren: "MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia." in: Cancer genetics and cytogenetics, Vol. 168, Issue 2, pp. 162-7, (2006) (PubMed).

Target Details for MLL/KMT2A

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Alternative Name: MLL (MLL Products)

Synonyms: ALL-1 antibody, CXXC7 antibody, HRX antibody, HTRX1 antibody, MLL antibody, MLL/GAS7 antibody, MLL1A antibody, TET1-MLL antibody, TRX1 antibody, WDSTS antibody, 6430520K01 antibody, All1 antibody, Cxxc7 antibody, Mll antibody, Mll1 antibody, mKIAA4050 antibody, lysine methyltransferase 2A antibody, lysine (K)-specific methyltransferase 2A antibody, KMT2A antibody, Kmt2a antibody

Background:

Description: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.

Aliases: MLL

Gene ID: 4297

HGNC: 4297

UniProt: Q03164

Pathways: Warburg Effect